Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: Data of subgroup analyses from MO19390 (SAiL) study

Clinical and Translational Oncology

Volumn 16, Issue 5, 2014, Pages 463-468

  Zhou, C C ^a   Bai, C X ^b   Guan, Z Z ^c   Jiang, G L ^b   Shi, Y K ^d   Wang, M Z ^e   Wu, Y L ^f   Zhang, Y P ^g   Zhu, Y Z ^h  

^a SHANGHAI PULMONARY HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d CANCER HOSPITAL   (China)

^e PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^f GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^g ZHEJIANG CANCER HOSPITAL   (China)

^h CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bevacizumab; Chemotherapy; Chinese; Non small cell lung cancer; VEGF

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLEEDING; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM METASTASIS; CHINESE; CLOSED ANGLE GLAUCOMA; CONNECTIVE TISSUE DISEASE; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; EYE DISEASE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 4 CLINICAL TRIAL; PNEUMOTHORAX; PROTEINURIA; THROMBOCYTOPENIA; URINARY TRACT DISEASE; VENOUS THROMBOEMBOLISM; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; LUNG NEOPLASMS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 84900802283     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1102-5     Document Type: Article

References (15)

1. Ahmedin J, Freddie B, Melissa MC, Jacques F, Elizabeth W, David F. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Qingsheng W, Xiaoping L. Lung cancer epidemiology in Mainland China. Chin J Clin Oncol. 2006;3:244-53.
3. Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2003;41:81-9.
4. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
6. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-42.
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel- carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50.
8. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-91.
9. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227-34.
10. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2747-54.
11. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9.
12. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11:733-40.
13. Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC results from the phase IV MO19390 (SAiL) study. J Thorac Oncol. 2011;6:1092-7.
14. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program. 2006. http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcaev3.pdf.
15. Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, Hida T, et al. Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. J Clin Oncol. 2009;27:15s (Abstr 8036)